Empagliflozin

Drug Profile

Empagliflozin

Alternative Names: BI-10773; Jardiance

Latest Information Update: 13 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly; Yale University
  • Class Antihyperglycaemics; Benzhydryl compounds; Cyclic ethers; Glucosides; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Type 2 diabetes mellitus
  • Phase III Type 1 diabetes mellitus
  • Phase II Heart failure

Most Recent Events

  • 27 Jun 2017 Phase-II clinical trials in Heart failure in USA (unspecified route) (NCT03027960)
  • 12 Jun 2017 Boehringer Ingelheim and Eli Lilly plan a clinical trial for Chronic kidney disease
  • 21 Mar 2017 Boehringer Ingelheim and Eli Lilly plan the phase III EMPEROR HF-Reduced trial for Heart failure (NCT03057977)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top